Last Updated on August 21, 2025
Navigating digital consent in Europe: A guide for US-based pharma companies and biotechs that want to enter European market
Expanding into Europe presents a lucrative opportunity for pharmaceutical companies and new Biotechs, but it also brings strict regulatory challenges, especially regarding digital communications with healthcare professionals (HCPs). Unlike the U.S., where promotional emails can be sent without prior consent, Europe mandates explicit optin consent before outreach can begin. Understanding and adapting to these regulations is key to a successful entry.
Regulatory landscape: GDPR & ePrivacy directive
Pharma companies must comply with GDPR (General Data Protection Regulation) and the ePrivacy Directive, which govern personal data collection and digital communication. These regulations require companies to:
- Obtain clear, documented consent before sending marketing materials to HCPs
- Offer easy optout mechanisms and maintain a transparent data usage policy
- Provide a full audit trail of consent collection to avoid compliance risks
Why this matters for pharma and biotech
Noncompliance isn’t just a legal issue, it affects trust. European HCPs expect personalized and fully compliant digital interactions. Companies that respect consent gain credibility, leading to better engagement and longterm partnerships.
Best practices for pharma expansion:
- Centralized Consent Management: Adopt a global preference management platform to track consent across multiple channels.
- Omni-Channel Compliance: Ensure email, webinars, events, and social media adhere to optin requirements.
- Data Quality & Audit Trails: Leverage match & merge algorithms to maintain clean HCP records and meet regulatory standards.
- Scalability: With digital channels, you can reach more doctors faster than just with sales reps.
- Cost-efficiency: keep your feet on the ground limited and use them for your top HCPs or easily accessible (distance) HCPs.
Pharma companies that prioritize digital trust not only avoid legal pitfalls but also build stronger relationships with European HCPs. In a landscape where consent is key, compliance becomes a competitive advantage.
